The FDA approved Obagi saypha ChIQ on June 15 for cheek augmentation and correction of midface contour deficiencies in patients over 21, giving Obagi its second filler in the US injectable portfolio. The first, saypha MagIQ, cleared in September 2025, so this is a deliberate buildout of a line rather than a one-off. ChIQ uses Croma-Pharma's MACRO Core Technology to form a stable 3D HA matrix, and Croma is not a newcomer to manufacturing: it has produced over 130 million syringes across the saypha line globally.

The more useful signal for a practice deciding whether to stock another filler family is in the interim ALOHA program data. 94% of injectors said they view MagIQ as complementary to the fillers they already use rather than a replacement, and 42.6% of MagIQ practices have gone on to evaluate Obagi skincare. That second number is the quiet part: the filler is functioning as a door into the broader Obagi catalog. Worth weighing if you are already an Obagi skincare account and looking to consolidate vendors.

Source: Waldencast / Obagi Medical (via StockTitan/GlobeNewswire) — https://www.stocktitan.net/news/WALD/obagi-medical-announces-fda-approval-of-obagi-saypha-ch-iqtm-jrbzt6fkq4l5.html